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Longitudinal Analysis of Tigecycline Activity against US
Isolates of Staphylococcus aureus Based on Patient Loca-
tion and Specimen Source
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Dowzicky2, D.F. Sahm1
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Background: Tigecycline (TIG) is a novel glycylcycline
that was approved in 2005 in the US for treatment of
complicated skin and skin structure infections and compli-
cated intra-abdominal infections. S. aureus (SA), including
methicillin-resistant S. aureus (MRSA), is a leading cause of
skin and skin structure infections. This study examines the
in vitro activity of TIG against SA, including MRSA, over the
last ﬁve years. Additionally, data were stratiﬁed according
to patient location (PL) and specimen source (SS) to deter-
mine if any variation in TIG activity against SA was apparent
among these subpopulations.
Methods: SA isolates were collected from multiple loca-
tions across all nine US Bureau of Census regions during
’03—’04 (N = 1,796), ’05 (N = 1,802), and ’06—’07 (N = 1,800)
and centrally tested using broth microdilution according to
current CLSI standards. TIG activity was analyzed by patient
locations (PL; outpatient [OP], intensive-care unit [ICU], and
inpatient non-ICU [IP]) and by specimen source (SS; blood
[BL], respiratory [RP], and skin and skin structure [SST]).
FDA breakpoints were used to interpret all TIG MIC results.
Results: Against SA overall, TIG had an MIC50/90
of 0.12/0.12mg/L in ’03—’04 and an MIC50/90 of
0.12/0.25mg/L in both ’05 and ’06—’07. Throughout the
study periods, percent susceptibility (%S) of TIG remained
≥99.5%. TIG activity by MIC90 was largely unaffected
by methicillin susceptibility status of the isolate (MIC90:
0.12mg/L for MSSA and 0.25mg/L for MRSA in ’03—’04,
0.25mg/L for MSSA and MRSA in ’05, and ’06—’07). In each
study period, the activity of TIG by MIC90 was identical
among all PL (OP, ICU, and IP) and SS (BL, RP, SST) evalu-
ated relative to TIG activity against SA overall. In the most
recent study period (’06—’07), SA isolates were ≥99% S to
TIG regardless of PL or SS.
Conclusion: By MIC90, TIG in vitro activity was stable
against SA over the past ﬁve years spanning both its devel-
opment and introduction to use and the %S of SA isolates to
TIG remained unaltered and high (>99.5%). TIG activity by
MIC90 was not notably affected by the methicillin suscepti-
bility status of the isolate and was consistent across all PL
and SS evaluated.
doi:10.1016/j.ijid.2008.05.704
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Activity of Telavancin Against Contemporary Streptococ-
cus spp. Pathogens: Recent Results from a European
Surveillance Program (2007)
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Background: -haemolytic streptococci (BHS), viridans
group streptococci (VGS) and Streptococcus pneumoniae
(SPN) are commonly occurring Gram-positive pathogens
responsible for a variety of local and systemic infections.
We evaluated potency of telavancin and comparators against
isolates belonging to these species/groups as part of a global
surveillance protocol for 2007. Telavancin is an investi-
gational, intravenous, semi-synthetic, rapidly bactericidal
lipoglycopeptide broadly active against both aerobic and
anaerobic Gram-positive bacteria and has been evaluated
in two Phase 3 complicated skin and skin structure infection
trials.
Methods: Non-duplicate clinical isolates (1087 total) of
BHS (339), VGS (100) and SPN (648) were submitted from
medical centres in Europe (23), Turkey (2) and Israel (1)
participating in surveillance for 2007. Identiﬁcations were
conﬁrmed by the central monitor and isolates were tested
using CLSI broth microdilution.
Results: Against BHS, SPN and VGS, telavancin potency
was most similar to penicillin (MIC50 values, 0.03 vs
≤0.015—0.06mg/L, respectively) and superior to other com-
parators; all tested isolates were inhibited by ≤0.25mg/L
of telavancin. Telavancin inhibited all VGS and SPN
at ≤0.12mg/L, including penicillin-non-susceptible strains
(27.0% and 30.2%, respectively), and BHS at ≤0.25mg/L.
Telavancin was most active against Group A BHS (MIC90,
0.03mg/L) compared with Groups B and G (0.06 and
0.12mg/L, respectively). All streptococci were suscep-
tible to vancomycin and linezolid, and BHS and VGS
were susceptible to daptomycin. While most strains were
susceptible to levoﬂoxacin (95.0—99.4%), resistance to ery-
thromycin/penicillin were variable (41.0/4.0%, 13.6/0.0%
and 33.6/19.3% for VGS, BHS and SPN, respectively).
Conclusions: Telavancin was broadly active against 2007
European streptococcal isolates. Based on MIC50 values, tela-
vancin was most similar to penicillin in ‘by weight’ activity
against SPN, BHS and VGS (all MICs, ≤0.25mg/L). Continued
monitoring for resistance among Gram-positive cocci will be
critical in assessing long-term efﬁcacy of this potent agent.
doi:10.1016/j.ijid.2008.05.705
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Background: The optochin susceptibility test remains
the primary and in some cases the only method in clini-
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cal laboratories to differentiate Streptococcus pneumoniae
(Pneumococci) from other -heamolytic streptococci. How-
ever, presence of optochin resistant pneumococci may lead
to misidentiﬁcation that will cause a compromise with treat-
ment and prevention of pneumococcal diseases. The typical
optochin susceptibility of Pneumococci resides in the Fo
complex of its FoF1 H+-ATPase, an ion transport enzyme that
is essential for the viability of this organism. Mechanism of
optochin resistance has been attributed to a single point
mutation in amino acid residues of the H+-ATPase c-subunit
(atpC).
Objective: To validate the preserved isolates and iden-
tify optochin-resistant pneumococci by bile solubility test
and PCR for lytA gene and to determine the mechanism of
optochin resistance.
Methodology: Alpha hemolytic streptococci isolated from
4,730 nasopharyngeal swabs of children <5 years old. The
isolates were validated by colony morphology, optochin sus-
ceptibility, bile solubility, PCR for lyt A (autolysin) and
ATPase c-subunit genes and sequencing to detect any AA
mutations.
Results: In total, 1618 -haemolytic isolates were vali-
dated; 111(6.86%) were Optr -heamolytic strains and only
37 (0.8%) were pneumococcus that were bile soluble and
possessed lytA gene. The PCR of atpC from all 37 strains
showed the presence of F0 complex in F0F1 H+-ATPase.
Sequencing of atpC gene of three strains when compared
with reference strain (opts strain R6) revealed the presence
of nucleotide change that produces AA substitution in ATPase
c-subunit protein.
Conclusion: Optochin resistant Streptococcus pneumo-
niae was ﬁrst observed in Bangladesh. A single point
mutation in H+-ATPase c-subunit gene that contributed for
Optr phenotype. Reporting of Opt pneumococci as viridans
streptococcus might have signiﬁcant implications for the
treatment and outcome of patients. Therefore, validation of
-haemolytic streptococci as pneumococci by bile solubility
test and/or PCR should be made.
doi:10.1016/j.ijid.2008.05.706
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Multisensitive Panton-Valentine Leukocidin-Positive
Methicillin-Resistant Staphylococcus aureus in Kuala
Lumpur, Malaysia
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Background: Recent years have seen the emergence of
methicillin-resistant Staphylococcus aureus (MRSA) strains
often characterised by community acquisition, unusual
susceptibility to antimicrobials, and the Panton-Valentine
leukocidin (PVL) virulence factor. The epidemiology of these
strains varies between geographical locations. This study
aimed to determine the occurrence and clinical features
of such strains in the University of Malaya Medical Centre,
Kuala Lumpur.
Methods: Laboratory records were examined for MRSA
isolates from 2002—2007. Using CLSI disc diffusion stan-
dards, multisensitive MRSA was deﬁned as susceptibility to
erythromycin, clindamycin, fusidic acid, rifampicin, gen-
tamicin, ciproﬂoxacin, cotrimoxazole, and tetracycline. PCR
detection of mecA and PVL genes lukS-PV-lukF-PV, SCCmec
typing, and MLST were carried out. The PVL product was
conﬁrmed by sequencing. Only cases with isolates avail-
able for PCR conﬁrmation were included in clinical records
review. Centers for Diseases Control and Prevention crite-
ria were used to distinguish between community-associated
(CA-MRSA) and healthcare-associated MRSA.
Results: Multisensitive MRSA from 13 distinct patient-
episodes were identiﬁed; 1 in 2003, 2 in 2006, and 10 in 2007
(0.27%, 0.62%, and 3.1% of new MRSA cases, respectively). 9
isolates from 2007 were available for mecA conﬁrmation. Of
these, only 2 were PVL-positive CA-MRSA; the remaining 7
were healthcare-associated, of which 3 were PVL-positive.
All isolates were of SCCmec type IV. There were 3 isolates of
each sequence type (ST) ST30 and ST6, 1 ST22 strain, and 2
untypeable isolates. Clinical presentations included skin or
soft-tissue infections (6), probable colonisation (2 babies),
bacteraemia (1), and no deaths. All 4 isolates unavailable
for conﬁrmation were healthcare-associated.
Conclusion: We describe the ﬁrst conﬁrmed clinical infec-
tions with multisensitive, SCCmec type IV, PVL-positive MRSA
in Malaysia, which were mainly skin or soft-tissue infections.
In view of the predominance of healthcare-associated acqui-
sition, and the apparent increase in cases in 2007 (albeit
small numbers), further work including multilocus sequence
typing is necessary to fully understand the local epidemiol-
ogy of MRSA.
doi:10.1016/j.ijid.2008.05.707
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Background: Daptomycin is a cyclic lipopeptide approved
for the treatment of complicated skin and soft tissue infec-
tions (cSSTI), right sided infective endocarditis (RIE) due to
Staphylococcus aureus (SA) and for SA bacteraemia when
associated with RIE or with cSSTI. We evaluated the activ-
ity of daptomycin and comparator agents tested against
multidrug-resistant (MDR) Gram-positive organisms isolated
in European hospitals.
Methods: 23,269 Gram-positive organisms were col-
lected through the Daptomycin Surveillance Program in
the 2003—2007 period, including SA (11,836), coagulase-
negative staphylococci (CoNS; 4,445), enterococci (4,464),
viridians group streptococci (VGS; 756) and beta-haemolytic
streptococci (BHS; 1,768). Isolates were consecutively col-
lected from patients with documented infections in 32
European hospitals (14 countries) and susceptibility tested
by CLSI broth microdilution methods against daptomycin and
>20 comparators. Mueller-Hinton broth was supplemented
to a 50mg/L calcium concentration for testing daptomycin.
MDR was deﬁned as resistance to drugs in 3 or more antimi-
crobial classes.
